GMCL1

Across TCGA pan-cancer cohorts, GMCL1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GMCL1 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GMCL1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GMCL1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, SKCM, and CESC are the cancer types where GMCL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.318	0.814	<.001	27	view →
SKCM	OS	Median	All	0.232	0.787	.002	27	view →
CESC	OS	Median	III,IV	0.091	0.755	<.001	24	view →
UCEC	DFS	Median	All	1.000	0.624	.022	18	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GMCL1–LUAD (OS)

Open the LUAD breakdown →